Contact Us

The Global CDMO Market Size to Surpass USD 143 Billion by 2027, States DelveInsight

“According to the latest report published by DelveInsight “Contract Development and Manufacturing Organization (CDMO) Market Insight,” the global Contract Development and Manufacturing Organization market is expected to witness appreciable growth owing to the growing prevalence of various diseases such as cancers, cardiovascular diseases among others. Moreover, the rising popularity of biologics is further expected to aid in the growth of the Contract Development and Manufacturing Organization market as these organizations offer a comprehensive solution to the biopharmaceutical companies for manufacturing biologic drugs. Additionally, the benefits of CDMO services are also motivating companies to get involved in various business transactions such as mergers & acquisitions and collaborations are also driving the Contract Development and Manufacturing Organization market. This report will provide an in-depth understanding of the Contract Development and Manufacturing Organization which will further benefit the competitors or stakeholders operating in the Contract Development and Manufacturing Organization market.”

Read full story

April 28, 2022

Center for Breakthrough Medicines (CBM) Strengthens Capabilities to Meet Demand

CBM is a contract development and manufacturing organization (CDMO) focused on Viral Vector and Plasmid Manufacturing

“As the Center for Breakthrough Medicines (CBM), a contract development and manufacturing organization (CDMO) focused on addressing the challenges associated with manufacturing advanced therapies, continues its rapid growth, the organization wanted to install an Enterprise Resource Planning (ERP) system to support its continued expansion and provide the highest level of responsive service to clients.

CBM’s Chief Executive Officer, Joerg Ahlgrimm pointed to the rapid growth CBM is currently undergoing with 700,000 square feet of ongoing build as one reason for the need for a robust ERP. This year, CBM selected SAP Business ByDesign, as a GMP validated system that covers the organization’s finances, client project management, supply chain planning, logistics, warehousing, manufacturing, and quality and procurement.

“We decided we needed to put in the right foundational platforms as early as possible,” Ahlgrimm said. In order to put that system in place as hassle-free as possible, CBM turned to Utah-based Navigator Business Solutions to support their efforts. “Navigator helped us do this the right way.”

Audrey Greenberg, Co-founder of CBM, agreed, saying that Navigator’s knowledge of cloud-based systems was of utmost importance to CBM when it was shopping around for implementation partners.

“We were looking for a group that’s responsive, competent and accommodating,” Greenberg said of their decision to hire Navigator. “They have the experience and track record of helping clients implement the platform.””

Read Full Story

April 26, 2022

Achilles Therapeutics Expands UK and U.S. Manufacturing Capabilities

“Achilles Therapeutics plc, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, is expanding its clinical manufacturing in the United Kingdom and the United States.

Achilles’ manufacturing facility at the Cell & Gene Therapy Catapult (Catapult) in Stevenage, UK, has received a manufacturing license from the Medicines and Healthcare products Regulatory Agency (MHRA) and, separately, the company has entered into a partnership agreement for clinical manufacturing with the Center for Breakthrough Medicines (CBM), a contract development and manufacturing organization in King of Prussia, Pennsylvania.

The additional peak annual capacity of up to 600 doses of the company’s personalized clonal neoantigen-reactive T cell product candidates, known as cNeT, will support clinical manufacturing in the two ongoing Phase I/IIa CHIRON and THETIS clinical trials in non-small cell lung cancer and melanoma, respectively.”

Read full story

April 24, 2022

Center for Breakthrough Medicines latest deal is with London biotech firm Achilles Therapeutics

CBM is a contract development and manufacturing organization (CDMO) working on Assay and Bioassay Development

“The Center for Breakthrough Medicines continued a busy year of deal-making by entering into a partnership with a London biotechnology firm.

Under the agreement, the King of Prussia contract development and manufacturing organization will provide Achilles Therapeutics (NASDAQ: ACHL) with the expanded cell therapy manufacturing it needs to supply products for its ongoing clinical trials.

Financial terms of the deal are being kept confidential.

Achilles is focused on developing precision T-cell therapies to treat solid tumors. Its lead cell therapy candidates are targeting advanced non-small cell lung cancer and metastatic melanoma.

Founded in 2016, Achilles recently established its U.S. headquarters in Philadelphia.

“[The Center for Breakthrough Medicine’s] King of Prussia location was perfect for our needs,” said Edward Samuel, the company’s executive vice president of technical operations. “The expertise of their team, along with their ability to provide on-demand, flexible access to autologous cell therapy manufacturing space was vital in our decision.”

John Lee, who was recently named vice president and head of cell therapy at the Center for Breakthrough Medicines, said the partnership “brings together two powerful, experienced cell therapy organizations for the benefit of cancer patients.”

The Center for Breakthrough Medicines is based within MLP Ventures’ Discovery Labs innovation hub campus. The site was previously home to a GlaxoSmithKline research and development complex.”

Read Full Story

April 18, 2022

Spotlight On: Audrey Greenberg, Co-Founder, Center for Breakthrough Medicines

Invest: spoke with Audrey Greenberg, co-founder of the Center for Breakthrough Medicines, to discuss the immense value Montgomery County and Philadelphia brings to the life sciences sector, both in investment and innovation. “Center for Breakthrough Medicines (CBM) provides preclinical through commercial development, manufacturing and testing of cell and gene therapies. CBM offers process development, plasmid DNA, viral vector and cell therapy manufacturing, and analytical services all under one roof to accelerate the development and commercialization of advanced therapies,” Greenberg said.

What makes Montgomery County a great location for the Center for Breakthrough Medicines?

Attracting and retaining talent is key to CBM’s growth, and Montgomery County offers the perfect environment for us to do so. We are surrounded by parks, trails, waterways, historic sites, entertainment, dining, cultural offerings and the finest public and private schools in the country. University City, the Jersey Shore, and the Poconos are just miles away offering urban exploration, beaches and mountains. This is coupled with an amazing suburban lifestyle including mission critical transportation infrastructure with easy access to our international airport, robust cold chain networks, the pharma belt, top-notch restaurants, hotels, and housing at various price points.  The King of Prussia Mall and Town Center offer dining, shopping, and recreation.

CBM is in the center of the most advanced healthcare in the region. Philadelphia is the birthplace of our nation and the birthplace of cell and gene therapy, providing a rich history as well as an ecosystem of life science companies, including large pharma, startups, academic and training institutions and advocacy organizations. Merck, GSK, J&J, AmerisourceBergen, Children’s Hospital of Philadelphia, Main Line Health plus a growing number of leaders in cell and gene therapy are located here.

The future of medicine is in Cellicon Valley. The Greater Philadelphia Region has seen an unprecedented increase in venture capital funding with $8 billion raised in 2021 and 43.5% year-over-year growth from 2020 to 2021. This is higher growth than the Bay Area, New York, Boston and Los Angeles and second only to Miami in deal value growth. One of the biggest problems facing cell and gene therapies is access to development services, manufacturing capacity and advanced analytics. Cell and gene therapies require specific expertise, equipment, raw materials, distribution networks and training.

Read full story

April 13, 2022

The Center for Breakthrough Medicines (CBM) Strikes Multi-Year Deal with UK Cell Therapy Powerhouse

Strategic Partnership to Deliver US Based Manufacturing Capacity for Novel Cell Therapy

King of Prussia, PA — April 12, 2022The Center for Breakthrough Medicines (CBM) announced today a partnership with London-based Achilles Therapeutics plc (NASDAQ: ACHL). The deal provides expanded cell therapy manufacturing capabilities required to supply products for Achilles’ ongoing Phase I/IIa clinical trials in advanced non-small cell lung cancer and metastatic or recurrent melanoma patients. CBM is a contract development and manufacturing organization (CDMO) dedicated to addressing the challenges associated with developing and manufacturing advanced therapies. Achilles is a clinical-stage biopharmaceutical company developing precision T-cell therapies to treat solid tumors.

“We are bringing together two powerful, experienced cell therapy organizations for the benefit of cancer patients,” said John Lee, Ph.D., Vice President, Head of Cell Therapy, CBM. “We look forward to mobilizing our world-class cell therapy capabilities, with our first wave of cell therapy suites to enable Achilles to accelerate the development of their flagship precision T cell product candidate.”

“Achilles is thrilled to partner with CBM given their experience, capabilities, available cell therapy capacity and strategic location. After opening our US headquarters in Philadelphia, CBM’s King of Prussia location was perfect for our needs,” said Edward Samuel, Executive Vice President of Technical Operations at Achilles Therapeutics. “The expertise of the CBM team, along with their ability to provide on-demand, flexible access to autologous cell therapy manufacturing GMP space was vital in our decision.”

CBM will manufacture Achilles’ precision T cell therapy for the company’s ongoing Phase I/IIa clinical trials in non-small cell lung cancer and melanoma patients.

“Our ability to deliver customizable manufacturing solutions for partners seeking autologous cell therapy production positions us well with Achilles, and we are excited to support them on their journey to bring desperately needed treatment options to cancer patients,” said Audrey Greenberg, co-founder, CBM. “We employ the most sophisticated scheduling, supply chain and inventory control systems integrated with industry-leading comprehensive in-process testing, quality control, and lot release programs in the industry. Achilles’ goal to deliver improved therapies to cancer patients also aligns with CBM’s mission and culture.”

About The Center for Breakthrough Medicines (CBM)
CBM is a purposefully built advanced therapy contract development and manufacturing organization (CDMO) based in the heart of Philadelphia’s Cellicon Valley. CBM offers pre-clinical through commercial manufacturing capabilities including process development, plasmid DNA, viral vector, cell therapy and a full suite of testing and analytical capabilities. Through a single-source, end-to-end solution, CBM accelerates time to market without compromising quality.

About Achilles Therapeutics
Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.

###

Contact:
Keith Bowermaster
Coyne PR
(o) 973-588-2168 (c) 770-891-9247
kbowermaster@coynepr.com

April 12, 2022

Money Matters TV #22-15 with Audrey Greenberg

CBM is a CDMO focused on Viral Vector, Cell Therapy and Plasmid Manufacturing

April 8, 2022